Post hoc pooled analysis of two phase 3 trials (787 patients with moderately to severely active ulcerative colitis): etrasimod vs placebo improved patient-reported symptomatic response from day 2 (difference 5.6%) and symptomatic remission from day 11 (4.7%).
Secondary analysisn = 787
Dubinsky et al. Rapid symptomatic improvement with etrasimod in ulcerative colitis: a post-hoc analysis of the ELEVATE UC program